ACL injuries are common. There are an estimated 2,6M ACL injuries annually globally, and about a third of them require reconstruction. Z-Lig is designed to make ACL reconstruction procedures easier for patients and surgeons
- The Z-Lig device as an immunocompatible, porcine-derived ACL reconstruction alternative which potentially provides a readily available, off-the-shelf solution and is strong, sterile, and reproducible.
- The Z-Lig has been granted CE Mark approval for revision and multi-ligament ACL reconstruction procedures
- It is the first and only solution of it’s kind, with 14 patents worldwide.
Aperion Biologics, Inc. developed and patented a technique to make animal-tissues usable for human applications without causing rejection.
The core platform technology is an enzymatic stripping of the key carbohydrate antigens followed by a unique conversion process that both “humanizes” and sterilizes the tissues without affecting their biomechanical or biological properties. This tissue scaffold provides mechanical stability and function while being biologically integrated and remodeled.
Rejection is the major obstacle preventing the use of animal derived tissue in human transplantation. Historically, tissue rejection was addressed by complete tissue crosslinking incorporating associated antigens into a non-remodelable prosthesis, much like leather. The complete crosslinking process renders a “permanent” tissue implant that inhibits human host cells of being incorporated and remodeled into natural biological tissue. Previous attempts at developing an animal derived tissue device have failed due to inflammation or adverse biological reactions.
To solve the xenotransplant rejection problems mentioned above, Aperion developed the Z-Process™. The Z-Process™ is a proprietary process that immunochemically modifies animal tissue to be compatible with the human immune system. Aperion uses α-galactosidase enzyme to cleave the terminal α-gal antigen so that the carbohydrate chain remaining on the animal tissue is the same in its structure as the carbohydrate chains present in humans. The Z-Process™ deactivates both αalpha-gal and non-gal antigens on the xenograft tissue to prevent rejection.
Aperion’s proprietary method addresses both the xenograft rejection as well as the ability to encourage a biological response to an implant.
The Z-Lig device as an immunocompatible, porcine-derived ACL reconstruction alternative which provides a readily available, off-the-shelf solution and is strong, sterile, and reproducible. The manufacturing process and subsequent product are protected by over 14 issued patents.
Aperion’s Z-Process™ of humanizing and sterilizing tissue can be applicable to a variety of tissues from orthopedic ligaments, bone, and meniscus to valves and vessels to soft tissue grafts for augmentation and repair.
Read about the Z-Lig Clinical Trial